Berkman N, Kremer S, Or R, Lossos I S, Christensen T G, Goldstein R H, Breuer R
Lung Cellular and Molecular Biology Laboratory, Institute of Pulmonology, Hadassah University Hospital and Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Respiration. 2001;68(2):169-77. doi: 10.1159/000050488.
Bleomycin (Bleo)-induced lung injury in mice serves as an animal model of pulmonary fibrosis. The pathogenesis of pulmonary fibrosis remains unclear, but it comprises both inflammatory and fibrotic components. The cytokine interferon (IFN)-alpha is produced by macrophages and may modulate both fibrogenesis and the determination of T lymphocyte phenotype in pulmonary fibrosis.
To investigate the effect of two preparations of recombinant IFN-alpha (IFN-alphaA/D and IFN-alpha2a) on Bleo-induced lung injury in C57BL/6 mice.
Mice were treated by a single intratracheal (IT) instillation of 0.06 mg of Bleo in 0.1 ml of saline or saline alone. One of two different IFN-alpha preparations, IFN-alphaA/D or IFN-alpha2a in saline, or saline alone were administered by daily intraperitoneal injections starting 1 day prior to IT instillation. The treatment groups were as follows: IT Bleo and intraperitoneal saline; IT Bleo and intraperitoneal IFN-alpha2a; IT Bleo and intraperitoneal IFN-alphaA/D; IT saline and intraperitoneal IFN-alphaA/D or IFN-alpha2a; IT saline and intraperitoneal saline. The animals were sacrificed 14 days after IT instillation. Lung injury was evaluated by total and differential cell count in bronchoalveolar lavage (BAL) fluid, by a semiquantitative morphological index of lung injury and a quantitative image analysis of cellularity and fibrosis fraction and by biochemical analysis of lung hydroxyproline content.
In Bleo-treated mice, IFN-alpha2a treatment caused a significant rise in BAL lymphocytes and in cellularity and fibrosis fractions in lung tissue. In contrast, IFN-alphaA/D treatment had no effect on Bleo-induced lung injury.
IFN-alpha may enhance Bleo-induced lung injury but this effect varies with different IFN preparations.
博来霉素(Bleo)诱导的小鼠肺损伤是肺纤维化的动物模型。肺纤维化的发病机制尚不清楚,但它包括炎症和纤维化成分。细胞因子干扰素(IFN)-α由巨噬细胞产生,可能在肺纤维化中调节纤维生成和T淋巴细胞表型的确定。
研究两种重组IFN-α制剂(IFN-αA/D和IFN-α2a)对C57BL/6小鼠博来霉素诱导的肺损伤的影响。
小鼠经气管内(IT)单次滴注0.06mg博来霉素于0.1ml盐水中或仅滴注盐水。两种不同的IFN-α制剂(IFN-αA/D或IFN-α2a溶于盐水中)或仅盐水,在IT滴注前1天开始每日腹腔注射。治疗组如下:IT博来霉素和腹腔注射盐水;IT博来霉素和腹腔注射IFN-α2a;IT博来霉素和腹腔注射IFN-αA/D;IT盐水和腹腔注射IFN-αA/D或IFN-α2a;IT盐水和腹腔注射盐水。IT滴注14天后处死动物。通过支气管肺泡灌洗(BAL)液中的总细胞计数和分类细胞计数、肺损伤的半定量形态学指标以及细胞数量和纤维化分数的定量图像分析,以及肺羟脯氨酸含量的生化分析来评估肺损伤。
在博来霉素治疗的小鼠中,IFN-α2a治疗导致BAL淋巴细胞以及肺组织中的细胞数量和纤维化分数显著增加。相比之下,IFN-αA/D治疗对博来霉素诱导的肺损伤没有影响。
IFN-α可能会增强博来霉素诱导的肺损伤,但这种作用因不同的IFN制剂而异。